ArticleInflammopharmacology2026
Topical 10% sulfasalazine ointment attenuates imiquimod-induced psoriasiform inflammation in mice compared with clobetasol.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPsoriasis is a chronic, immune-mediated disease with an overabundance of cytokines and aberrant keratinocyte proliferation.
objectiveTo assess the therapeutic activity of topical application of 10% sulfasalazine in an imiquimod-induced murine model and to compare its therapeutic activity with that of clobetasol. METHODOLOGY: Thirty-two male mice were randomly assigned into four groups, with each group consisting of eight individuals: normal control group, IMQ + vehicle group, IMQ + clobetasol group, and IMQ + 10% sulfasalazine group. IMQ was administered for 7 days, and then daily topical application was conducted for 14 days. Lesion severity was determined by PASI scores, and histological scores and concentrations of TNF-α and IL-6.
resultsBoth sulfasalazine and clobetasol led to significant reduction in PASI scores, compared to IMQ + vehicle (p < 0.05). The regimen of sulfasalazine improved epidermal structure, acanthosis, and inflammation, as well as.
conclusionTopical sulfasalazine was found to possess significant anti-inflammatory activity, both clinical and histological, against IMQ-induced inflammation resembling psoriasis.
Indexed as
Identifiers
41543819What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.